Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.598
-0.012 (-1.90%)
At close: Feb 21, 2025, 4:00 PM
0.609
+0.011 (1.77%)
After-hours: Feb 21, 2025, 5:20 PM EST
Karyopharm Therapeutics Stock Forecast
KPTI's stock price has decreased by -50.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Karyopharm Therapeutics stock have an average target of 5.00, with a low estimate of 3.00 and a high estimate of 7.00. The average target predicts an increase of 735.56% from the current stock price of 0.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $3 | Buy | Reiterates | $3 | +401.34% | Feb 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,069.79% | Feb 20, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $3 | Buy | Reiterates | $3 | +401.34% | Feb 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,069.79% | Jan 15, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +735.56% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
152.56M
from 146.03M
Increased by 4.47%
Revenue Next Year
163.77M
from 152.56M
Increased by 7.35%
EPS This Year
-0.65
from -1.25
EPS Next Year
-0.73
from -0.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 161.7M | 204.8M | 237.0M | |||
| Avg | 152.6M | 163.8M | 199.2M | |||
| Low | 141.8M | 128.3M | 152.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.7% | 34.2% | 44.7% | |||
| Avg | 4.5% | 7.3% | 21.7% | |||
| Low | -2.9% | -15.9% | -6.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.63 | -0.44 | -0.29 | |||
| Avg | -0.65 | -0.73 | -0.55 | |||
| Low | -0.67 | -1.19 | -1.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.